Global Assets Advisory LLC Buys Shares of 14,544 Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Global Assets Advisory LLC acquired a new position in Pfizer Inc. (NYSE:PFE – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 14,544 shares of the biopharmaceutical company’s stock, valued at approximately $417,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Atlas Capital Advisors LLC raised its position in shares of Pfizer by 54.4% during the first quarter. Atlas Capital Advisors LLC now owns 1,702 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 600 shares during the period. Sovereign Financial Group Inc. grew its holdings in shares of Pfizer by 12.2% during the first quarter. Sovereign Financial Group Inc. now owns 16,929 shares of the biopharmaceutical company’s stock valued at $470,000 after buying an additional 1,837 shares in the last quarter. Wealthcare Advisory Partners LLC grew its holdings in shares of Pfizer by 149.7% during the first quarter. Wealthcare Advisory Partners LLC now owns 129,868 shares of the biopharmaceutical company’s stock valued at $3,604,000 after buying an additional 77,868 shares in the last quarter. Edge Wealth Management LLC grew its holdings in shares of Pfizer by 2.0% during the first quarter. Edge Wealth Management LLC now owns 260,180 shares of the biopharmaceutical company’s stock valued at $7,220,000 after buying an additional 5,121 shares in the last quarter. Finally, Vanguard Capital Wealth Advisors grew its holdings in shares of Pfizer by 4.2% during the first quarter. Vanguard Capital Wealth Advisors now owns 10,217 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 412 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PFE. Sanford C. Bernstein assumed coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday. Finally, Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $33.91.

Check Out Our Latest Analysis on Pfizer

Pfizer Trading Up 0.1 %

Pfizer stock opened at $28.86 on Thursday. The business has a 50 day moving average price of $29.07 and a two-hundred day moving average price of $28.48. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock has a market cap of $163.54 billion, a price-to-earnings ratio of -481.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.82%. Pfizer’s dividend payout ratio is currently -2,800.00%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also